Skip to content
OpenCapital
Get started

Repligen RGEN EBITDA margin

EBITDA margin at other companies

TEC
Bio-TechneTECH
23.4%-8.3pp
Revvity logo
RevvityRVTY
26.6%-2.0pp
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
24.2%-0.2pp
Danaher logo
DanaherDHR
29.2%-0.9pp
Agilent Technologies logo
Agilent TechnologiesA
25.3%-0.2pp
Charles River Laboratories logo
Charles River LaboratoriesCRL
17.5%-2.2pp

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×—
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Calculated from Repligen’s reported figures.

ebitda/total revenue=12.4%

Based on trailing twelve months.

The official record: Repligen’s 10-Q, filed November 18, 2024, on SEC EDGAR. View the filing →

Ask your AI about Repligen's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's EBITDA margin?
Repligen (RGEN) reported EBITDA margin of 12.4% in Q3 2024.
How has Repligen's EBITDA margin changed year-over-year?
Repligen's EBITDA margin decreased by 51.2% year-over-year, from 25.4% to 12.4%.
What is the long-term trend for Repligen's EBITDA margin?
Over 3 years (2020 to 2023), Repligen's EBITDA margin has grown at a -8.0% compound annual growth rate (CAGR), from 26.5% to 20.6%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.